In prior studies where we focused on aberrant glycosylation in cancer cells, we demonstrated that disruption of the galactose metabolism pathway by siRNAs against GALT inhibited the growth of HepG2 cells in culture and proposed that GALT is a novel therapeutic target for HCC [13]. This evidence concerns the gene GALT and cancer.